Skip to main content
S&P 5007,606.88+0.28%DOW52,040.67-0.10%NASDAQ26,152.90+0.66%BTC$75,693.00-0.62%ETH$2,389.74-0.93%GOLD$4,388.40+1.28%OIL$102.60-3.05%
Smart Investors Daily
Bausch + Lomb Corporation logo

NASDAQ · BLCO

Bausch + Lomb Corporation

Healthcare · Medical - Instruments & Supplies

$17.23

Down-$0.05 (-0.29%)

Updated Sep 16, 2026, 4:52 PM

SID Score

5.5/10

Composite research score

Smart Money

54/100

Neutral

Market cap
6.12B
P/E ratio
-20.07
Dividend yield
0.00%
52-week range
$13.77 – $18.92
Volume
361.55K
Avg. volume
492.22K

Price performance

BLCO price history

1M range · 20 trading sessions · Daily adjusted prices

BLCO closed at $17.23 after 20 trading sessions, up 1.12% for the selected period.

Last close
$17.23
Period change
+1.12%
Period low
$17.04
Period high
$18.14
Daily close
View OHLC price history
BLCO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$17.65$17.65$17.15$17.23361.55K
Sep 14, 2026$17.44$17.66$17.25$17.58205.4K
Sep 11, 2026$17.79$17.79$17.01$17.25460.18K
Sep 10, 2026$17.69$17.76$17.395$17.55521.45K
Sep 9, 2026$17.80$18.205$17.63$17.79484.93K
Sep 8, 2026$17.80$17.96$17.47$17.73335.61K
Sep 4, 2026$17.92$18.17$17.86$18.04414.11K
Sep 3, 2026$18.22$18.27$17.77$18.14298.66K
Sep 2, 2026$17.94$18.465$17.865$18.00358.6K
Sep 1, 2026$17.65$17.9463$17.63$17.88645.49K
Aug 31, 2026$17.01$17.51$17.00$17.48624.85K
Aug 28, 2026$17.16$17.30$16.94$17.15403.11K
Aug 27, 2026$17.28$17.39$16.95$17.13559.31K
Aug 26, 2026$17.33$17.35$17.05$17.25350.9K
Aug 25, 2026$17.44$17.44$17.00$17.25476.33K
Aug 24, 2026$17.29$17.56$17.21$17.32290.49K
Aug 21, 2026$17.29$17.45$17.16$17.24239.92K
Aug 20, 2026$17.33$17.47$17.04$17.20411.81K
Aug 19, 2026$17.26$17.77$17.26$17.45537.95K
Aug 18, 2026$17.06$17.49$17.04$17.04429.48K

Latest BLCO news

The latest Smart Investors Daily articles mentioning BLCO.

Stock researchCompany · Overview

BLCO research

Overview

Company profile and research snapshot.

Company profile

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$18.00
Implied upside
—
Analysts
20
BLCO recent ratings
DateFirmRatingTarget
Sep 15, 2026NeedhamHold—
Sep 9, 2026Leerink PartnersOutperform—
Aug 28, 2026HC Wainwright & Co.Buy—
Aug 3, 2026HC Wainwright & Co.Buy—
Jul 30, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

VAUGHAN, Ontario, September 11, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneous

Yahoo · Sep 2, 2026

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

VAUGHAN, Ontario, September 02, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meetin

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By